Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 16Carcinoma, Renal Cell 13Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Myelodysplastic Syndromes 5Lung Neoplasms 5Prostatic Neoplasms 4Leukemia, Myeloid, Acute 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Ovarian Neoplasms 3Histiocytoma, Malignant Fibrous 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Penile Neoplasms 2Nasopharyngeal Carcinoma 2Meningioma 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioblastoma 2

Interventions

Doxorubicin 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 3cabozantinib 2Ifosfamide 2tremelimumab 1talimogene laherparepvec 1regorafenib 1peposertib 1pazopanib 1olaratumab 1liposomal doxorubicin 1futibatinib 1fludarabine 1eribulin 1durvalumab 1avelumab 1aldesleukin 1X-Rays 1Trabectedin 1Standard of Care 1Quality of Life 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × CTLA-4 Antigen × 1 year × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

NCT03307616 2026-03-05

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡